Direct compression of high-dose ferrous bisglycinate for adult iron deficiency anemia is configured around a target elemental iron dose of 60 mg per unit, which at an API lot assay of 20% Fe w/w requires 300 mg of ferrous bisglycinate per tablet core. In a 700 mg total core mass, this places the API fraction at 42.9% w/w; production batches with API lot assays of 19–22% Fe w/w must adjust the API mass proportionally between 272.7 mg and 315.8 mg to maintain label claim. Compliance for this dosage form rests on USP <905> for content uniformity, USP <711> for dissolution testing in 0.1 N hydrochloric acid at 37 ± 0.5 °C, USP <1216> for tablet friability, USP <921> for residual moisture, and ICH Q3D Table A.2.2 for elemental impurity limits in oral drug products. The downstream process on a rotary tablet press, for example a Fette 2090i with 43 stations, uses pre-compression force of 5–8 kN and main compression force of 15–25 kN; turret speed is held between 30 rpm and 60 rpm because higher speeds reduce dwell time and increase capping risk when the API fraction exceeds 45% w/w. Formulation addition ratio must also account for magnesium stearate at 0.5–1.0% w/w, crospovidone disintegrant at 4–6% w/w, and microcrystalline cellulose plus mannitol at combined 35–45% w/w; exceeding 1.5% w/w magnesium stearate or extending V-blender lubrication beyond 5 min at 12 rpm reduces wetting and slows 45-min dissolution by more than 15% compared with the same formulation lubricated for 3 min. Finished terminal product types are biconvex, round, film-coated tablets packaged in aluminum/PVC blister format, with film coating applied to limit surface oxidation and to reduce tooth discoloration caused by direct contact between ferrous glycinate and enamel under low salivary pH.

Pediatric Orodispersible Iron Binder Selection and Saliva pH Limits

Pediatric orodispersible and chewable iron presents a process conflict between dose loading and organoleptic acceptability; ferrous bisglycinate suppresses free Fe(II) better than ferrous sulfate at salivary pH, but the benefit is lost if the chelate is destabilized by acidulants or if tablet porosity allows early saliva ingress. Typical addition ratio is 7.5–30 mg elemental iron per unit, requiring 37.5–150 mg ferrous bisglycinate at an assay of 20% Fe w/w. In a 300 mg orodispersible tablet, the API fraction is capped at 20% w/w to maintain disintegration below 30 s; higher pediatric doses shift to 600 mg chewable units where API fraction may reach 25–35% w/w. Compliance references include USP <701> for disintegration, USP <905> for uniformity of dosage units, USP <711> for dissolution in pH 1.2 followed by pH 4.5 media where regional approvals require, ICH Q3D Table A.2.2, and 21 CFR 211.110 for in-process blend uniformity. Production is direct compression using mannitol 60–75% w/w, crospovidone 5% w/w, sucralose 0.2–0.5% w/w, a berry or cocoa masker at 0.3–0.8% w/w, and magnesium stearate 0.7% w/w. Compression force is kept between 6 kN and 12 kN; tablet hardness is controlled at 30–50 N, friability at <1.0% per USP <1216>, and moisture at <1.5%. Citric acid and other acidulants should remain below 1.0% w/w because localized pH depression weakens the glycine chelate and raises the metallic taste threshold above 10 µg/g free Fe(II) in simulated saliva at pH 6.8–7.4. Terminal product types are orodispersible tablets and chewable tablets in aluminum/aluminum blister packaging for tropical climates.

Hard capsule filling for once-daily prenatal iron and iron-folic acid programs uses ferrous bisglycinate to avoid the metallic aftertaste interference that appears with ferrous sulfate in two-piece capsules, but the API introduces flow and compressibility constraints on automatic dosing disc fillers. Addition ratio is 50–100 mg elemental iron per capsule, corresponding to 250–500 mg ferrous bisglycinate at 20% Fe w/w, with a fill weight of 500–800 mg in size 00 or 000 HPMC capsules; typical API fraction is 45–65% w/w. Compliance is anchored to USP <701> for disintegration, USP <711> for dissolution, USP <2040> for capsule shell assessment, and ICH Q3D Table A.2.2. Downstream production begins with a dry pre-blend and, when API bulk density is <0.35 g/mL or Carr index exceeds 35, a roller compaction step is required before capsule filling. Capsule filling on a Bosch GKF 2600 or equivalent runs at 30,000–80,000 capsules/h; mass variation is targeted at ±3% with a maximum deviation of ±5%. Pre-drying is required if water activity exceeds 0.60, and residual moisture is held below 2.5%. Terminal finished product types are hard gelatin or HPMC capsules in HDPE bottles with desiccant or cold-form aluminum blisters.

If Ferrous Bisglycinate Granules Are Metered Into Stick Packs at Fill Weights Below 1.0 g, Which Sieve Cut Prevents Demixing?

When ferrous bisglycinate granules are filled into unit-dose stick packs below 1.0 g, the controlling variable is not the iron content but the particle size distribution that prevents API-rich fines from migrating to the bottom of the fill chamber. Addition ratio is 15–60 mg elemental iron per sachet, requiring 75–300 mg ferrous bisglycinate per unit. In a 500 mg fill weight delivering 30 mg elemental iron, the API fraction is 30% w/w, leaving 350 mg for binder, disintegrant, flow aid, and sweetness carrier. Compliance for granules includes USP <905> for uniformity of dosage units, USP <711> for dissolution using the 0.1 N HCl method, USP <670> for container-closure integrity of stick pack material, and ICH Q3D Table A.2.2. The granulation process uses a high-shear mixer with impeller tip speed 5.0 m/s and chopper 1500 rpm; water addition is 6–10% w/w, wet massing 60–120 s, and fluid-bed drying inlet 55–65 °C with product temperature <40 °C and LOD <2.0%. Milling through a 1000 µm screen is followed by segregation of the 125–500 µm granule fraction; the API D50 should be 75–180 µm, and granule bulk density after drying should be 0.45–0.70 g/mL. If API fraction exceeds 60% w/w or API D50 falls below 75 µm, segregation occurs on vertical form-fill-seal equipment with auger fillers at speeds above 60 stick packs/min. Terminal product types are oral granules in stick packs, sachets, or multi-dose HDPE bottles with a desiccant cap.

Injectable dosage form development with ferrous bisglycinate is constrained by the absence of a compendial parenteral monograph and the chelate’s low molecular weight of 203.9 g/mol for the anhydrous form relative to intravenous iron carbohydrate complexes. Compliance expectations for any exploratory parenteral work include USP <788> for particulate matter in injections, USP <790> for visible particulates, USP <85> for bacterial endotoxins, Ph. Eur. 5.1.1 for methods of sterilisation, and ICH Q3D Table A.2.3 for parenteral elemental impurity limits. Formulation addition ratio is not established in any current pharmacopoeia or EPAR, and no marketed injectable ferrous bisglycinate product has been identified. If an R&D batch is required for preclinical feasibility, the only cautious starting point is 0.1–0.5 mg elemental iron/mL in citrate or lactated buffer under nitrogen, but published data for this specific configuration is limited, and the solution is not appropriate for clinical administration without toxicity and pharmacokinetic data. The production process would require WFI at <10 °C, nitrogen purging to maintain residual oxygen below 0.2 mg/L, and sterile filtration through a 0.22 µm PVDF membrane; terminal sterilisation is not feasible because the glycine chelate degrades under autoclave thermal load. Terminal finished product types are not defined; the route remains an exploratory formulation study rather than a standard industrial output.